Some forms of tumour immunity can be stimulated by infusion of monoclonal antibodies; for example, targeting receptors on tumour cells such as Her2 [73], or inhibiting feedback mechanisms in the immune system such as PD1/PD-L1 engagement [74,75]. Here, ERBB2 is linked to neoplasm.